The results of the phase III ORIENT-32 study were released in a late-breaking oral presentation at the European Society of Medical Oncology Asia (ESMO Asia) Virtual Congress 2020.

The phase III, randomized, open-label,multi-centre ORIENT-32 study evaluated the efficacy and safety of sintilimab in combination with IBI305 (anti-vascular endothelial growth factor (VEGF), monoclonal antibody) compared to sorafenib as the first-line treatment for advanced hepatocellular carcinoma (HCC).

A total of 571 patients were enrolled in the trial. Based on an interim analysis Tyvyt (sintilimab injection) in combination with Byvasda demonstrated significantly improved overall survival (OS) and Independent Radiographic Review Committee (IRRC) progression-free survival (PFS) versus sorafenib. Compared to sorafenib, Tyvyt plus Byvasda demonstrated a 43.1% decreased risk of all-cause mortality (HR 0.569, 95%CI: 0.431‒0.751, p < 0.0001); the median OS was not reached in the Tyvyt plus Byvasda arm versus 10.4 months in the sorafenib arm. Tyvyt plus Byvasda also demonstrated 43.5% decreased risk of progression as assessed by the IRRC (HR 0.565 95%CI: 0.455‒0.701, p < 0.0001); median PFS was 4.6 months in the Tyvyt plus Byvasda arm versus 2.8 months in the sorafenib arm.

The primary outcome measures of the study (OS and PFS) were ‘significantly improved’ and ‘generally consistent across all subgroups’, according to Innovent. Innovent also said that the combination regimen also ‘showed an acceptable safety profile with no new safety signals’. The company concluded that ‘with these results, Tyvyt plus Byvasda could potentially provide a new option for the first-line treatment of patients with advanced HCC’.

Innovent announced that it had received approval for Byvasda from China’s National Medical Products Administration (NMPA), formerly the China Food and Drug Administration (CFDA), back in June 2020 [1].

Related articles
Copy biological approvals in China, compared to the US and EU

Copy biologicals approved in China

Biosimilars of bevacizumab

Reference
1. GaBI Online - Generics and Biosimilars Initiative. China approves bevacizumab copy biological Byvasda [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2021 Jan 15]. Available from: www.gabionline.net/Biosimilars/News/China-approves-bevacizumab-copy-biological-Byvasda 

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2021 Pro Pharma Communications International. All Rights Reserved.